{"id":53228,"date":"2026-01-07T20:51:58","date_gmt":"2026-01-07T12:51:58","guid":{"rendered":"https:\/\/flcube.com\/?p=53228"},"modified":"2026-01-07T20:52:00","modified_gmt":"2026-01-07T12:52:00","slug":"novo-nordisk-lilly-cut-china-prices-for-wegovy-mounjaro-by-up-to-80","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53228","title":{"rendered":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%"},"content":{"rendered":"\n<p><strong>Novo Nordisk (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>)<\/strong> and <strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> have lowered list prices for their top\u2011selling obesity drugs <strong>Wegovy<\/strong> and <strong>Mounjaro<\/strong> in China by <strong>48\u201180%<\/strong> in a strategic move to defend market share against domestic competitors and ahead of <strong>semaglutide patent expiry<\/strong> in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-price-cuts-overview\">Price Cuts Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Dosage<\/th><th>Previous Price (\u00a5\/month)<\/th><th>New Price (\u00a5\/month)<\/th><th>Reduction<\/th><th>Effective Date<\/th><\/tr><\/thead><tbody><tr><td><strong>Wegovy<\/strong><\/td><td>Highest dose (2.4mg)<\/td><td>1,899<\/td><td>987<\/td><td><strong>48%<\/strong><\/td><td>Jan\u202f1\u202f2026<\/td><\/tr><tr><td><strong>Wegovy<\/strong><\/td><td>Medium dose<\/td><td>2,470<\/td><td>1,284<\/td><td><strong>48%<\/strong><\/td><td>Jan\u202f1\u202f2026<\/td><\/tr><tr><td><strong>Mounjaro<\/strong><\/td><td>10mg pen<\/td><td>2,180<\/td><td>~445<\/td><td><strong>80%<\/strong><\/td><td>Jan\u202f1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Source<\/strong>: Provincial procurement platforms and online pharmacies (JD Health, Ali Health).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-pressure\">Market Context &amp; Competitive Pressure<\/h2>\n\n\n\n<p><strong>China GLP\u20111 Market Dynamics<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size<\/strong>: <strong>\u00a518\u202fbillion<\/strong> (2025), projected <strong>\u00a545\u202fbillion<\/strong> by 2030 (35% CAGR)<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: <strong>100\u202fmillion+<\/strong> obese adults; <strong>diagnosis rate &lt;5%<\/strong><\/li>\n\n\n\n<li><strong>Current Coverage<\/strong>: <strong>&lt;1%<\/strong> of eligible patients receive branded GLP\u20111 therapy due to high cost<\/li>\n<\/ul>\n\n\n\n<p><strong>Domestic Competition<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hangzhou Zhongmei<\/strong> (GLP\u20111 biosimilar): <strong>\u00a5600\u2011800<\/strong> monthly<\/li>\n\n\n\n<li><strong>Jiangsu Hengrui<\/strong> (tirzepatide biosimilar): <strong>\u00a5500\u2011700<\/strong> monthly<\/li>\n\n\n\n<li><strong>Shandong Luye<\/strong> (oral semaglutide): <strong>\u00a5400\u2011600<\/strong> monthly<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Imperative<\/strong>: Price cuts are <strong>defensive<\/strong> to maintain <strong>20\u201130%<\/strong> market share vs. <strong>60\u201170%<\/strong> share for domestic players by 2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-patent-expiry-catalyst\">Patent Expiry Catalyst<\/h2>\n\n\n\n<p><strong>Semaglutide Patent Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Expiry<\/strong>: <strong>2026<\/strong> (formulation patents)<\/li>\n\n\n\n<li><strong>US\/EU Expiry<\/strong>: <strong>2031\u20112032<\/strong><\/li>\n\n\n\n<li><strong>Impact<\/strong>: <strong>15\u201120 generic\/biosimilar<\/strong> entrants expected in China by <strong>Q4\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Mounjaro Patent Status<\/strong>: <strong>Tirzepatide patents expire 2036+<\/strong> globally, but Lilly\u2019s aggressive pricing aims to <strong>pre\u2011empt semaglutide generics<\/strong> and <strong>lock in early market share<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-volume-strategy\">Financial Impact &amp; Volume Strategy<\/h2>\n\n\n\n<p><strong>Novo Nordisk China Revenue<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025<\/strong>: <strong>\u00a53.2\u202fbillion<\/strong> (Wegovy + Ozempic)<\/li>\n\n\n\n<li><strong>2026E Post\u2011Cut<\/strong>: <strong>\u00a54.5\u20115.0\u202fbillion<\/strong> (volume surge offsetting price drop)<\/li>\n\n\n\n<li><strong>Margin Impact<\/strong>: <strong>Gross margin<\/strong> on Wegovy drops from <strong>92% to 78%<\/strong>, but <strong>operating margin<\/strong> remains <strong>45\u201150%<\/strong> due to scale<\/li>\n<\/ul>\n\n\n\n<p><strong>Eli Lilly China Revenue<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025<\/strong>: <strong>\u00a5800\u202fmillion<\/strong> (Mounjaro)<\/li>\n\n\n\n<li><strong>2026E Post\u2011Cut<\/strong>: <strong>\u00a52.8\u20113.2\u202fbillion<\/strong> (300\u2011400% volume increase projected)<\/li>\n<\/ul>\n\n\n\n<p><strong>Net Impact<\/strong>: Both companies trade <strong>price for volume<\/strong>, expecting <strong>2\u20113x patient growth<\/strong> to offset <strong>50\u201180% price reductions<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-reimbursement-amp-access-pathway\">Reimbursement &amp; Access Pathway<\/h2>\n\n\n\n<p><strong>NRDL Strategy<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Status<\/strong>: Neither drug is <strong>National Reimbursement Drug List (NRDL)<\/strong> covered for obesity<\/li>\n\n\n\n<li><strong>Post\u2011Price Cut<\/strong>: <strong>Pivotal for 2026 NRDL negotiation<\/strong> (price threshold typically <strong>\u00a51,000\u20111,500\/month<\/strong>)<\/li>\n\n\n\n<li><strong>Outcome<\/strong>: <strong>Novo aims for conditional NRDL inclusion<\/strong> in <strong>H2\u202f2026<\/strong>; <strong>Lilly already submitted Mounjaro<\/strong> at new price<\/li>\n<\/ul>\n\n\n\n<p><strong>Hospital Access<\/strong>: Price cuts enable <strong>inclusion in 2,000+ tertiary hospitals<\/strong> (vs. <strong>800 currently<\/strong>), expanding from <strong>tier\u20111 cities<\/strong> to <strong>tier\u20112\/3 markets<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-response\">Competitive Response<\/h2>\n\n\n\n<p><strong>Domestic Players<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zhongmei<\/strong>: <strong>Held price at \u00a5700<\/strong>, gaining <strong>premium positioning<\/strong> for quality\u2011conscious consumers<\/li>\n\n\n\n<li><strong>Hengrui<\/strong>: <strong>Dropped to \u00a5450<\/strong> (matching Mounjaro), triggering <strong>price war<\/strong> in tier\u20112 cities<\/li>\n\n\n\n<li><strong>Luye<\/strong>: <strong>Oral semaglutide at \u00a5500<\/strong> offers <strong>convenience advantage<\/strong> over injectables<\/li>\n<\/ul>\n\n\n\n<p><strong>Investor Implication<\/strong>: <strong>Margin compression across GLP\u20111 sector<\/strong>; winners will be those with <strong>lowest COGS<\/strong> and <strong>broadest distribution<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding price cut sustainability, volume uptake, NRDL inclusion probability, and competitive market share shifts. Actual results may differ materially due to regulatory decisions, domestic player responses, and patient adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,4361,148,911,860,86],"class_list":["post-53228","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-eli-lilly","tag-hot-targets","tag-novo-nordisk","tag-nyse-lly","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53228\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53228\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T12:51:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T12:52:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%\",\"datePublished\":\"2026-01-07T12:51:58+00:00\",\"dateModified\":\"2026-01-07T12:52:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: LLY\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53228#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53228\",\"name\":\"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T12:51:58+00:00\",\"dateModified\":\"2026-01-07T12:52:00+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53228\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53228#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80% - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53228","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%","og_description":"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.","og_url":"https:\/\/flcube.com\/?p=53228","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T12:51:58+00:00","article_modified_time":"2026-01-07T12:52:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53228#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53228"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%","datePublished":"2026-01-07T12:51:58+00:00","dateModified":"2026-01-07T12:52:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53228"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","Hot targets","Novo Nordisk","NYSE: LLY","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53228#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53228","url":"https:\/\/flcube.com\/?p=53228","name":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T12:51:58+00:00","dateModified":"2026-01-07T12:52:00+00:00","description":"Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their top\u2011selling obesity drugs Wegovy and Mounjaro in China by 48\u201180% in a strategic move to defend market share against domestic competitors and ahead of semaglutide patent expiry in 2026. The price cuts, effective January\u202f1, 2026, position both companies to capture volume in the world\u2019s fastest\u2011growing GLP\u20111 market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53228#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53228"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53228#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53228"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53228\/revisions"}],"predecessor-version":[{"id":53230,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53228\/revisions\/53230"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}